Form 4: GeneDx CFO Kevin Feeley Reports Routine Stock Transactions for Tax Obligations

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, reported the acquisition of shares from restricted stock unit vesting and a subsequent sale to cover tax withholding obligations.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), reported transactions involving the company's Class A Common Stock.
• On June 1, 2025, Mr. Feeley acquired 718 shares of Class A Common Stock through the settlement of Restricted Stock Units (RSUs) at a price of $0 per share.
• Following this acquisition, on June 2, 2025, Mr. Feeley disposed of 370 shares of Class A Common Stock at a price of $71.26 per share.
• The sale of 370 shares was explicitly stated as a 'sell to cover' transaction, intended solely to satisfy tax withholding obligations related to the RSU vesting and settlement, and was not a discretionary transaction.
• After these reported transactions, Mr. Feeley beneficially owns 4,105 shares of Class A Common Stock directly.
• Additionally, Mr. Feeley holds 3,586 Restricted Stock Units (RSUs) directly, with a vesting schedule of 6.25% quarterly over a four-year period commencing December 1, 2022, contingent on continued service.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction by an insider to cover tax obligations related to RSU vesting, which is a standard practice and does not indicate any specific positive or negative outlook on the company's performance or future.

Future Outlook

The document indicates ongoing vesting of Restricted Stock Units (RSUs) for the reporting person, with 6.25% vesting quarterly over a 4-year period commencing December 1, 2022, subject to continued service.

Management Comments

• The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sales were to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, particularly for executives receiving equity compensation. It reflects standard compensation practices within the biotechnology and diagnostics sector, where equity incentives like RSUs are prevalent.

Stakeholder Impact

• Shareholders: The sale of 370 shares by the CFO is a small, non-discretionary transaction for tax purposes and is unlikely to have a material impact on the company's stock price or shareholder value.
• Employees: The RSU vesting and subsequent tax-related sale reflect standard equity compensation practices, which can be a positive for employee retention and alignment of interests.

Next Steps

• Continued quarterly vesting of the remaining 3,586 Restricted Stock Units (RSUs) for Kevin Feeley, subject to his continued service to GeneDx Holdings Corp.

Key Dates

Keywords

GeneDx Holdings Corp., WGS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, Chief Financial Officer, Kevin Feeley, Equity Compensation